Bio-Techne Corporation TECH
72.76 USD +0.09 (+0.13%)
Nov 6, 2026, 12:49 PM EST
72.63 Day range 72.79
43.30 52-week range 72.76
- YTD
- +23.71%
- 1 year
- +25.05%
News
prnewswire.com BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September…
zacks.com Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock? TECH's Q1 earnings are on deck, with revenues and EPS growth expected as investors weigh segment performance and the pending $11.3 billion acquisition.
benzinga.com Bio-Techne Opens New Bristol Facility Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applicationsNew Bristol facility expands GMP small molecule production capacity and complements recent…
benzinga.com Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the…
benzinga.com Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026 Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targetsMarket-based Scope 1 and 2 emissions reduced 49% year-over-yearMore…- benzinga.com Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73 Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
- benzinga.com Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 1.89 percent decrease over earnings of $0.53 per share from the same period…
benzinga.com Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.- benzinga.com RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73 RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Perform and raises the price target from $62 to $73.
benzinga.com TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73 TD Cowen analyst Kyle Boucher downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold and raises the price target from $65 to $73.
benzinga.com Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73 Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.- benzinga.com Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73 Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $68 to $73.
benzinga.com Baird Maintains Neutral on Bio-Techne, Raises Price Target to $73 Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Neutral and raises the price target from $49 to $73.- benzinga.com Bio-Techne To Pay Termination Fee Of $230.5M To Merck KGaA In Event That Deal Isn't Consummated; Merck KGaA To Pay Fee Of $576.1M If Deal Terminated Termination Fees The Company will be required to pay to Parent a termination fee equal to $230,455,000 (the "Company Termination Fee"): · If (A) the Merger Agreement is validly terminated (i) by…
benzinga.com Micron Rallies 15%, Apple Sinks 6% On Memory Costs: Stock Market Today Micron's blowout earnings powered memory and chip stocks higher, but the broad stock market rally stalled by midday as S&P 500 slipped.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
benzinga.com Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.
benzinga.com Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal Merck KGaA is acquiring Bio-Techne in an $11.3B all-cash deal to expand its life science, diagnostics, and bioprocessing footprint.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…- benzinga.com CORRECTION: Germany's Merck KGaA To Acquire Bio-Techne At $73 Per Share In Cash At EV $11.3B; Deal Expected To Be Immediately Sales Accretive And EBITDA Pre Margin Post-Closing And EPS Pre Accretive By Year 3 Post-Closing Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ:TECH), a Minneapolis-based global provider of life science tools, analytical technologies,…
- benzinga.com 'Activist Investor Ananym Urges Bio-Techne to Consider Selling' - Bloomberg News https://www.bloomberg.com/news/articles/2026-06-15/activist-investor-ananym-urges-bio-techne-to-consider-selling
benzinga.com Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65 Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neutral rating and announces Price Target of $65.
benzinga.com Bio‑Techne And Refeyn Launch An Integrated Workflow To Characterize Charge And Size Variants In Bispecific Antibodies And Biosimilars By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge…
benzinga.com RBC Capital Reinstates Outperform on Bio-Techne, Announces $62 Price Target RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announces $62 price target.- benzinga.com Citigroup Maintains Buy on Bio-Techne, Lowers Price Target to $70 Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $80 to $70.
- benzinga.com Wells Fargo Maintains Overweight on Bio-Techne, Lowers Price Target to $62 Wells Fargo analyst Brandon Couillard maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lowers the price target from $76 to $62.
- benzinga.com Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $50 Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $54 to $50.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.
benzinga.com Bio-Techne Q3 2026 Earnings Call: Complete Transcript - benzinga.com Bio-Techne Q3 Adj. EPS $0.53 Misses $0.54 Estimate, Sales $311.415M Miss $317.093M Estimate Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.53 per share which missed the analyst consensus estimate of $0.54 by 1.85 percent. This is a 5.36 percent decrease over earnings of $0.56…
- benzinga.com Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $54 Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $68 to $54.
benzinga.com Bio-Techne Expands COMET Solution Portfolio With Addition Of New SPYRE Focus Panels And SPYRE Amplification Kits New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential- benzinga.com Reported Monday, Bio-Techne Announces Ella Benchtop Immunoassay Platform Now CE-IVD Marked And Available For Sale Across The European Union Ella benchtop instrument is now CE-IVD marked and available for sale in the EUEnables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with…
- benzinga.com Wells Fargo Maintains Overweight on Bio-Techne, Raises Price Target to $76 Wells Fargo analyst Brandon Couillard maintains Bio-Techne (NASDAQ:TECH) with a Overweight and raises the price target from $70 to $76.
benzinga.com 7 Analysts Assess Bio-Techne: What You Need To Know - benzinga.com Citigroup Maintains Buy on Bio-Techne, Raises Price Target to $80 Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and raises the price target from $70 to $80.
- benzinga.com Stifel Maintains Hold on Bio-Techne, Raises Price Target to $65 Stifel analyst Daniel Arias maintains Bio-Techne (NASDAQ:TECH) with a Hold and raises the price target from $60 to $65.
- benzinga.com Earnings Scheduled For February 4, 2026
benzinga.com Recent Report Shows That Rep. April McClain Delaney Sold Up to $210K Worth of Bio-Techne Stock - benzinga.com Maryland Rep. April McClain Delaney Bought Up to $135K Worth of Bio-Techne Stock
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Bio-Techne's Simple Western Technology Utilized In FDA Approval Of ZEVASKYN, Developed By Abeona Therapeutics Bio-Techne Corporation (NASDAQ:TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous
- benzinga.com Earnings Scheduled For May 7, 2025
benzinga.com This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
benzinga.com This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
benzinga.com Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday? Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.- benzinga.com Earnings Scheduled For February 5, 2025
benzinga.com Stocks Rise On Core Inflation Slowdown, Banks Rally After Strong Q4 Earnings, Treasury Yields Plummet Major indices rallied on Wednesday after December inflation data showed underlying price pressures slowing, reducing fears of a prolonged pause in interest rate cuts by the Federal Reserve.